Navigation Links
Roche Opens New Center of Excellence Facility
Date:9/30/2011

NUTLEY, N.J., Sept. 30, 2011 /PRNewswire/ -- Roche announced today the opening of a new state-of-the-art clinical supply manufacturing facility on its campus in Nutley, N.J. The Roche Center of Excellence produces dosage forms of highly potent compounds for preclinical safety studies, and Phase 1 and 2 clinical studies. The 17,000 square foot facility houses specialized equipment to process potent compounds into medicines for clinical trials.

"This is a vitally important milestone for the Nutley site as well as Pharmaceutical Research and Early Development at Roche," said Waseem Malick, PhD, Vice President, Pharmaceutical & Analytical R&D. "It enables continued support of our portfolio, and is another example of Roche's commitment to Nutley as a major research center for Roche."

Plans for the facility were approved in May 2010 and construction began in August 2010. The clinical dosage forms produced by the facility include tablets, capsules, powders, suspensions and solutions. Scientists and engineers manufacture clinical supplies of highly active compounds under current Good Manufacturing Practices (cGMP) for Roche trials worldwide. It also contains warehouses for components, excipients (inactive ingredients) and active pharmaceutical ingredients (APIs), mechanical rooms and multipurpose isolation suites for manufacturing.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology:
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
(Date:4/28/2017)... FL (PRWEB) , ... April 28, 2017 , ... ... Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub ... is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The ... retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox ...
Breaking Medicine News(10 mins):